Suketu Upadhyay: Yes, sure. Jeff, I’ll take that, Suky again. I think the biggest driver was bone cement, not surprising when you see the recon growth numbers in the second quarter to see a very good other performance, especially for bone cement. We also saw some good performance outside in surgical as well, which also creeped up. Your last question inside of that was around ROSA placements versus outright sales. And consistent with prior commentary, we’re seeing the majority of our ROSA placements or installments, I should say, being done through the placement strategy versus sales. So that trend continues.
Jeffrey Johnson: All right. Great. And then maybe just a follow-up, just on backlog. I know you don’t guide on backlog and any high-level comments though on how you’re thinking about that backlog clearing in EMEA and what you saw in the U.S.? And just kind of comfort with that backlog still continuing to provide some tailwinds maybe over the coming year or 2? Thanks.
Suketu Upadhyay: Yes, definitely felt that in the second quarter as we talked about. That helped offset some of the supply challenges that we had. We expect backlog to continue to contribute through the rest of this year. It’s always difficult to determine exactly how much was in any given quarter and to predict how much will come through. It’s a little bit of amorphous, but we know that it’s there, and we have high confidence that it’s going to — we’re going to continue to see it through the back end of this year and likely through 2024.
Operator: We’ll go next to Larry Biegelsen with Wells Fargo.
Lawrence Biegelsen: Congrats on a nice quarter here. I’ll ask a couple on the pipeline. Persona iQ, do you guys have what you need now for a full launch from a clinical data standpoint — and if so, what data are you going to promote and file for the label? And I had one follow-up.
Ivan Tornos: Absolutely, Larry. I’ll take that one. First and foremost, we remain on track with our limited market release. We’ve been saying all along that by January Q1 of 2024, we’ll be ready for a full launch. And I will say that we’re almost there in gain on the data. We’re approaching 1 billion data points from multiple patients thousands of implants by now. And really we’re answering 3 questions. Number one is, to your point, what is the value proposition? Can we demonstrate a reduction in the length of the episode of care? Can we bring objectivity to a range of motion metrics? Can we demonstrate better gate performance given better technique, better surgery? Can we compare recovery curves? Who does better post implantation?
There’s a lot of data we get in that regard, and we’ll be filing some claims once we digest the multiple data points that we’re getting. So that’s question number one. Question number two in the limited market release is how do we make the whole thing seamless? This is new to the word technology. It’s got a home base station, as you know. It involves the patient, involves the surgeon, the caregiver. So we want to make sure that is a best-in-class experience, and there are some things that we’re working around. And then the third question, and I know this is near and dear to you is who’s going to pay for the technology? To that end, we got the NTAP kicking in at the beginning of October. You’ll be pleased to know that we follow up with your question around TPD, transitional pass-through.
We had a deadline of August 23 to submit. We’re in the final stages of evaluating what the submission could look like. We’re evaluating commercial payer strategy as part of this limited market release. So we continue to think about the payer as well. So with all of that said, the what, the how and the who will pay, I think going to be in a good position to start to see a full market release by January, if not late Q1 2024.
